Response: Dexamethasone dose alters expression of NK activating receptors in vivo

Blood

Volumn 118, Issue 24, 2011, Pages 6466-6468

  Hsu, Andy ^a   Quach, Hang ^b   Tai, Tsin ^a   Prince, H Miles ^c   Harrison, Simon J ^a   Trapani, Joseph A ^c   Smyth, Mark J ^c   Neeson, Paul J ^c   Ritchie, David S ^c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b MONASH UNIVERSITY   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; LENALIDOMIDE; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 1; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D;

CELL DEATH; DRUG MEGADOSE; HUMAN; LETTER; LOW DRUG DOSE; MULTIPLE MYELOMA; NATURAL KILLER CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

EID: 83455219319     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-10-382291     Document Type: Letter

References (5)

1. Carter CL, Feyler S, Smalle N, et al. Effect of combined dexamethasone/lenalidomide therapy on NK cell-receptor levels in myeloma patients. Blood. 2011;118(24):6465-6466.
2. Hsu AK, Quach H, Tai T, et al. The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. Blood. 2011;117(5):1605-1613.
3. El-Sherbiny YM, Meade JL, Holmes TD, et al. The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. Cancer Res. 2007;67(18):8444-8449. (Pubitemid 47437416)
4. Jinushi M, Vanneman M, Munshi NC, et al. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008;105(4):1285-1290. (Pubitemid 351397045)
5. Mitsiades CS. How "immunomodulatory" are IMIDs? Blood. 2011;117(5):1440-1441.